Arkolith/Insider Trading/RUBY/Form 4

Turka Laurence A.

Chief Scientific OfficerRubius Therapeutics, Inc. (RUBY) · full profile →Form 4 · filed Jan 31, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$622
Net Open-Market Flow
-$622
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2023Option exercise(M)9K——21K
Jan 31, 2023Sell(S)3K$0.24$62218K
Jan 29, 2023Option exercise(M)7K——12K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2023Option exercise(M)9K—$026K
Jan 29, 2023Option exercise(M)7K—$015K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-008873) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML